Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician  by Vassalotti, Joseph A. et al.
REVIEWPractical Approach to Detection and Management
of Chronic Kidney Disease for the Primary Care
Clinician
Joseph A. Vassalotti, MD,a,b Robert Centor, MD,c Barbara J. Turner, MD, MSED,d Raquel C. Greer, MD, MHS,e
Michael Choi, MD,e Thomas D. Sequist, MD, MPH,f National Kidney Foundation Kidney Disease Outcomes Quality Initiative
aIcahn School of Medicine at Mount Sinai, New York, NY; bNational Kidney Foundation, Inc, New York, NY; cUniversity of Alabama at
Birmingham School of Medicine; dUniversity of Texas Health Science Center at San Antonio; eJohns Hopkins University School of Medicine,
Baltimore, Md; fHarvard Medical School, Boston, Mass.Funding: Non
Conﬂict of In
Safety Board for G
Authorship: A
JAV and TD
nephrologists.
Requests for re
National Kidney F
E-mail address
0002-9343/ 201
licenses/by-nc-nd/
http://dx.doi.org/1ABSTRACT
A panel of internists and nephrologists developed this practical approach for the Kidney Disease Outcomes
Quality Initiative to guide assessment and care of chronic kidney disease (CKD) by primary care clinicians.
Chronic kidney disease is deﬁned as a glomerular ﬁltration rate (GFR) <60 mL/min/1.73 m2 and/or markers
of kidney damage for at least 3 months. In clinical practice the most common tests for CKD include GFR
estimated from the serum creatinine concentration (eGFR) and albuminuria from the urinary albumin-to-
creatinine ratio. Assessment of eGFR and albuminuria should be performed for persons with diabetes and/or
hypertension but is not recommended for the general population. Management of CKD includes reducing the
patient’s risk of CKD progression and risk of associated complications, such as acute kidney injury and
cardiovascular disease, anemia, and metabolic acidosis, as well as mineral and bone disorder. Prevention of
CKD progression requires blood pressure<140/90 mmHg, use of angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers for patients with albuminuria and hypertension, hemoglobin A1c 7% for
patients with diabetes, and correction of CKD-associated metabolic acidosis. To reduce patient safety haz-
ards from medications, the level of eGFR should be considered when prescribing, and nephrotoxins should
be avoided, such as nonsteroidal anti-inﬂammatory drugs. The main reasons to refer to nephrology specialists
are eGFR <30 mL/min/1.73 m2, severe albuminuria, and acute kidney injury. The ultimate goal of CKD
management is to prevent disease progression, minimize complications, and promote quality of life.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016)
129, 153-162
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0.1016/j.amjmed.2015.08.0252002, the National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative published the ﬁrst guideline that
deﬁned chronic kidney disease, independent of the cause, as
based on 3 or more months of either kidney damage (albu-
minuria, kidney biopsy ﬁndings, or imaging abnormalities) or
an estimated glomerular ﬁltration rate <60 mL/min/1.73 m2.1
Epidemiologic data have shown that low estimated glomerular
ﬁltration rate increases the risk of systemic complications (eg,
cardiovascular disease, hypertension, mineral and bone disor-
ders, and anemia),mortality, andprogression to end-stage renal
disease. Deﬁning chronic kidney disease as based on abnor-
malities in kidney function or albuminuria that persist at least 3ess article under the CC BY-NC-ND license (http://creativecommons.org/
154 The American Journal of Medicine, Vol 129, No 2, February 2016months distinguishes it from potentially preventable or
reversible acute kidney injury of less than 3 months’ duration.
Since 2002, this chronic kidney disease classiﬁcation has led to
estimated glomerular ﬁltration rate reporting added to serum
creatinine outpatient testing panels, and its incorporation into
diagnosis codes.2CLINICAL SIGNIFICANCE
 Chronic kidney disease (CKD) is deﬁned
by estimated glomerular ﬁltration rate
(eGFR) and urinary albumin/creatinine
ratio.
 The 4 interventions that reduce CKD
progression are blood pressure control
<140/90 mm Hg, use of angiotensin-
converting enzyme inhibitors or angio-
tensin receptor blockers for albuminuria
and hypertension, diabetes control, and
correction of metabolic acidosis.
 A patient safety approach to CKD con-
siders the level of eGFR in prescription
practice.
 Statin-based therapies reduce vascular
events in CKD.
 Nephrology referral for advanced CKD is
associated with improved outcomes.New data from 50 cohorts
totaling more than 2 million in-
dividuals has demonstrated a strong
and linear increase in the risk of
adverse outcomes for chronic kid-
ney disease according to the 2002
deﬁnition of an estimated glomer-
ularﬁltration rate<60mL/min/1.73
m2 or albumin-to-creatinine ratio
>30mg/g (>3mg/mmol).3 In 2012
the Kidney Disease Improving
Global Outcomes released a new
guideline for chronic kidney disease
that adds reﬁnements based on
cause, estimated glomerular ﬁltra-
tion rate, and albuminuria cate-
gories (see Appendix A [available
online] for guideline statements).4
Consideration of the cause of
chronic kidney disease fundamen-
tally affects management by dis-
tinguishing a systemic condition
from one that is localized to the
kidney, such as a glomerular dis-
ease. The albuminuria is comple-
mentary to low estimated
glomerularﬁltration rate because both independently inﬂuence
prognosis, as demonstrated by a heat map of the new classiﬁ-
cation illustrating an increasing risk of chronic kidney disease
progression, morbidity, and mortality (Figure 1).4 This
new grid offers a practical guide for primary care clinicians
to inform monitoring and management of chronic kidney
disease.
The estimated prevalence of chronic kidney disease in the
general population exceeds 10%,3,5 outstripping the avail-
ability of nephology specialists and requiring primary care
clinicians to care for the majority of these patients. A panel of
internists and nephrologists developed this practical approach
to guide assessment and care of chronic kidney disease by
primary care clinicians, described in the following sections
on detection, progression, patient safety, interaction with
cardiovascular disease, and nephrology referral.TOPIC 1: DETECTION OF CHRONIC KIDNEY DISEASE
Overview
Expert panels have identiﬁed insufﬁcient evidence to support
general population-based testing for chronic kidney dis-
ease.1,4,6-9 Both the Kidney Disease Outcomes Quality Ini-
tiative and the Kidney Disease Improving Global Outcomeschronic kidney disease guidelines have recommended targeted
testing for chronic kidney disease among high-risk populations
with diabetes and/or hypertension.1,4,9 In practice, detection of
chronic kidney disease often occurs during routine care
because serum creatinine testing is included in ubiquitous basic
and comprehensive metabolic panels. Early detection ofchronic kidney disease offers a
valuate opportunity to avert com-
plications before symptoms occur
and to slow loss of kidney function
over time.10-16
Compared with persons whose
chronic kidney disease remains un-
detected, those with chronic kidney
disease diagnosed by a primary care
clinician are more likely to avoid
risky use of nonsteroidal anti-
inﬂammatory drugs (NSAIDs)17;
use angiotensin-converting-enzyme
inhibitors (ACE-Is) or angiotensin
receptor blockers (ARBs) when
indicated17,18; and receive appro-
priate nephrology care.18
Kidney Function:
Estimated Glomerular
Filtration Rate
Detection of chronic kidney disease
based on estimated glomerular
ﬁltration rate is a more accurate
assessment of kidney function than
serum creatinine alone.1,4,9 Twoequations are used in practice to estimate glomerular ﬁltration
rate, the Chronic Kidney DiseaseeEpidemiology Collabora-
tion equation and the older Modiﬁcation of Diet in Renal
Disease Study equation. Recent studies have found that the
Chronic Kidney DiseaseeEpidemiology Collaboration equa-
tion more accurately predicts prognosis and is less biased than
the older Modiﬁcation of Diet in Renal Disease Study equa-
tion.4,9,19 One caveat is that any estimated glomerular ﬁltration
rate equation is inaccurate in the setting of acute kidney injury
because kidney function is not in a steady state.
Urine Studies to Evaluate for Albuminuria or
Proteinuria
Although quantiﬁcation of albuminuria has been less widely
adopted in clinical practice than assessment of estimated
glomerularﬁltration rate,5 it is crucial to evaluating prognosis.
A spot albumin-to-creatinine ratio is a more sensitive and
speciﬁc marker of chronic kidney disease than a spot urine
protein/creatinine ratio, although both are predictive of clin-
ical outcomes.9 Standardization of urine albumin measure-
ment is ongoing but superior to urine protein that has much
wider variability.9 A random or spot urine specimen quan-
tiﬁes albumin as milligrams per gram of creatinine (mg/g)
(Figure 1).4
Figure 1 Risk of chronic kidney disease progression, frequency of visits, and referral to
nephrology according to estimated glomerular ﬁltration rate (eGFR) and albuminuria. The GFR and
albuminuria grid depict the risk of progression, morbidity, and mortality by color, from best to worst
(green, yellow, orange, red, deep red). The numbers in the boxes are a guide to the frequency of visits
(number of times per year). Green can reﬂect CKD with normal eGFR and albumin-to-creatinine
ratio (ACR) only in the presence of other markers of kidney damage, such as imaging showing
polycystic kidney disease or kidney biopsy abnormalities, with follow-up measurements annually;
yellow requires caution and measurements at least once per year; orange requires measurements
twice per year; red requires measurements at 3 and deep red 4 times per year. These are general
parameters only, based on expert opinion and must take into account underlying comorbid conditions
and disease state, as well as the likelihood of impacting a change in management for any individual
patient. “Refer” indicates nephrology services are recommended. *Referring clinicians may wish to
discuss with their nephrology service, depending on local arrangements regarding treating or
referring. This ﬁgure is adapted with permission from reference 4.
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Evaluation with imaging or serologic testing to identify the
cause of chronic kidney disease is not routinely required,20
particularly in the presence of diabetes or hypertension.
Kidney and bladder ultrasound should be performed when
there is a history of urinary tract stones or obstruction,
frequent urinary tract infections, or a family history of poly-
cystic kidney disease.1 Serologic workup is only required
when a systemic or glomerular disease is suspected, such as
myeloma or amyloidosis. Consider nephrology referral when
the cause of kidney disease is not apparent, particularly for
patients without diabetes and hypertension.TOPIC 2: CHRONIC KIDNEY DISEASE
PROGRESSION AND COMPLICATIONS
Overview
The treatment of chronic kidney disease aims to delay pro-
gressive loss of kidney function and prevent or managecomplications. Four interventions clearly delay chronic kid-
ney disease progression, including management of hyperten-
sion; use of a renin angiotensin aldosterone system (RAAS)
blocker, anACE-I, or ARB for hypertension and albuminuria;
control of diabetes; and correction of metabolic acidosis.
Management to delay progression and treat chronic kidney
disease complications is discussed in the following sections.Hypertension Management
For the past 10 years, the Joint National Committee on hy-
pertension (JNC) has recommended an ofﬁce blood pressure
target of 130/80 mm Hg or less for patients with chronic
kidney disease.21 Recently, JNC 8 has loosened this target to
140/90 mm Hg, the same as for the general population
under 60 years of age.22 This new recommendation reﬂects
the lack of robust data supporting a lower blood pressure
target. Accordingly, recent clinical practice guidelines for
blood pressure management in chronic kidney disease have
suggested that a target of 130/80 mm Hg should be sought
156 The American Journal of Medicine, Vol 129, No 2, February 2016only in the context of severe albuminuria, but the evidence
for this goal is of very low quality.23 Sodium consumption is
an important consideration for blood pressure control in
chronic kidney disease. A diet high in sodium is a cause of
resistance to hypertension medications, especially for patients
with chronic kidney disease. The average American con-
sumes more than 3500 mg sodium daily.24 For patients with
chronic kidney disease current guidelines recommend less
than 2000 mg of sodium per day; however, there is low-
quality evidence for this recommendation.4,9,23-25ACE-I or ARB
Treatment with ACE-I or ARB for hypertension in persons
with chronic kidney disease with or without diabetes who
have A2 and A3 levels of albuminuria is supported by low- to
high-level evidence, respectively.23 Although JNC 8 recom-
mends a RAAS blocker for all patients with chronic kidney
disease,22 current evidence supports this treatment primarily
for patients with albuminuria. Some chronic kidney disease
patients can develop hyperkalemia or a decreased estimated
glomerular ﬁltration rate after starting an ACE-I or an ARB.
Monitoring should include assessment of serum potassium
and estimated glomerular ﬁltration rate approximately within
several weeks after initiation or dose escalation. When
hyperkalemia develops, outpatient management strategies
include identiﬁcation and restriction of dietary potassium,
treatment of metabolic acidosis if appropriate (see below),
consideration of thiazide or loop diuretic use to increase
potassium excretion, and treatment with a potassium-binding
exchange resin. Discontinuation of the RAAS blocker should
be considered only if these interventions fail. When the esti-
mated glomerular ﬁltration rate decreases more than 25%
within 3 months of RAAS initiation, the patient deserves
additional investigation for overdiuresis or renal artery
stenosis.Dual RAAS Blockade
Combination therapy with an ACE-I plus an ARB should
not be used for patients with chronic kidney disease and
hypertension regardless of whether they have diabetes. Trials
have shown greater complications, such as acute kidney
injury and severe hyperkalemia, and no mortality or car-
diovascular beneﬁts with combination versus single-agent
therapy.26,27Diuretic Therapy
Diuretics are generally necessary to manage extracellular
ﬂuid volume expansion and blood pressure control in
chronic kidney disease. Thiazides are used especially for
patients with stages G1-3b chronic kidney disease. A
second-line option is a loop diuretic when the thiazide does
not achieve volume control goals. Most patients with stage
G4 chronic kidney disease will require a loop diuretic, and
furosemide, the most common drug, should be dosed twice
daily for effective diuresis.Glycemic Control
According to recent data regarding harms from overly
intensive glycemic control, a target hemoglobin A1c (HbA1c)
of approximately 7% has been recommended, with a higher
target for those with a limited life expectancy or an elevated
risk of hypoglycemia.9,28 In addition to cardiovascular risk
reduction, the beneﬁts of glycemic control in chronic kidney
disease include reduced progression of albuminuria and
reduced loss of kidney function over time.14,16,28
Chronic Kidney Disease Anemia
Measurement of hemoglobin (Hb) at least annually is rec-
ommended beginning with stage G3a chronic kidney dis-
ease, because erythropoietin production decreases with low
glomerular ﬁltration rate.4,9 Figure 2 shows a summary of
chronic kidney disease anemia management.29ChronicKidneyDiseaseMineral andBoneDisorder
Secondary hyperparathyroidism, hypocalcemia, hyper-
phosphatemia, decreased vitamin D, and vascular calciﬁcation
typically begin in stage G3b, when serum calcium, phos-
phorus, intact parathyroid hormone, and total 25-hydroxy
vitamin D should be measured at least once to document
baseline levels. Figure 2 provides details onmanagement.30,31Chronic Kidney Disease Metabolic Acidosis
Treatment of chronic kidney diseaseeassociated metabolic
acidosis with oral alkali to achieve a normal serum bicar-
bonate level has been shown in observational studies to slow
chronic kidney disease progression.32-34 When the bicar-
bonate level is less than 22 mmol/L, sodium bicarbonate
(650 mg) should be prescribed 3 times daily. This dose
corresponds to approximately 23 mEq daily of sodium and
bicarbonate. Sodium citrate (30 mL daily) is an alternative,
corresponding to 30 mEq of sodium and bicarbonate each
day. If this does not result in a serum bicarbonate level of at
least 22 mmol/L, a nephrology referral is indicated.TOPIC 3: PATIENT SAFETY IN CHRONIC KIDNEY
DISEASE
Overview
Many commonly prescribed medications and/or their
metabolites are excreted by the kidneys. Dose adjustments
based on estimated glomerular ﬁltration rate need to be
performed to avert or reduce complications (Table 1).4,9,35
Several medications can cause acute kidney injury that,
in turn, can initiate and/or accelerate chronic kidney dis-
ease progression. It may be prudent to discontinue or
brieﬂy withhold medications that may cause acute kidney
injury (RAAS blockers, NSAIDs, diuretics) or those that
can cause complications (eg, lactic acidosis due to met-
formin) when patients have an increased risk of volume
depletion.
Figure 2 Summary of a practical approach to the detection and management of chronic kidney disease (CKD). ACE-I ¼ angiotensin-
converting enzyme inhibitor; ACR ¼ albumin-to-creatinine ratio; AKI ¼ acute kidney injury; ARB ¼ angiotensin receptor blocker;
ASA ¼ acetylsalicylic acid/aspirin; A stage ¼ albuminuria category; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease;
CKD-MBD ¼ chronic kidney disease mineral and bone disorder; CVA ¼ cerebrovascular accident; CVD ¼ cardiovascular disease;
DM ¼ diabetes mellitus; eGFR ¼ estimated glomerular ﬁltration rate; ESA ¼ erythropoietin-stimulating agent; G stage ¼ GFR
category; Hb ¼ hemoglobin; HTN ¼ hypertension; iPTH ¼ intact parathyroid hormone; NSAIDs ¼ nonsteroidal anti-inﬂammatory
drugs; 25-OH vit ¼ 25-hydroxy vitamin D; PICC ¼ peripherally inserted central catheter line; PT INR ¼ prothrombin timeeinter-
national normalized ratio; RAAS ¼ renin angiotensin aldosterone system.
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Nonsteroidal anti-inﬂammatory inhibitors can cause acute
kidney injury by inhibiting vasodilatory prostaglandins, es-
pecially in the context of other factors that impair renal
perfusion, such as dehydration and congestive heart failure.36
Long-term use of NSAIDs can also increase the rate of pro-
gression of chronic kidney disease.36,37 These drugs areavailable over the counter, so it is important that the clinician
speciﬁcally inquire about their use and educate patients about
potential harms. Other potential adverse effects of NSAIDS
include allergic interstitial nephritis with or without minimal
change disease, hyperkalemia, hypertension, and edema.36
These medications should be avoided with an estimated
glomerular ﬁltration rate <30 mL/min/1.73 m2 and limited
Table 1 Cautionary Notes for Prescribing in People with Chronic Kidney Disease
Agents Cautionary Notes for Common Outpatient Medications
Antihypertensives/cardiac medications
RAAS antagonists (ACE-I, ARB,
aldosterone antagonist, direct
renin inhibitor)
 Use with caution in patients with renal artery stenosis
 Start at lower dose in patients with GFR <45 mL/min/1.73 m2
 Assess GFR and serum potassium 1-2 weeks after starting or escalating dose
 Consider temporarily holding during IV contrast administration, or any potential cause of
volume depletion (bowel preparation prior to colonoscopy, acute illness, and surgery)
 Do not routinely discontinue when GFR <30 mL/min/1.73 m2 because they may remain
nephroprotective
b-Blockers  Reduce dose of hydrophilic b-blockers (acebutolol, atenolol, bisoprolol, and nadolol) by 50%
when GFR <30 mL/min/1.73 m2
Digoxin  Reduce dose according to plasma concentrations
Analgesics
NSAIDs  Avoid when GFR <30 mL/min/1.73 m2
 Prolonged therapy is not recommended when GFR <60 mL/min/1.73 m2
 Avoid when taking RAAS-blocking agents or lithium
Opioids  Reduce dose of renally excreted agents (morphine, hydrocodone, codeine) when GFR <60 mL/
min/1.73 m2
 Use with caution in patients with GFR <15 mL/min/1.73 m2
Antimicrobials
Macrolides
 Reduce dose by 50% when GFR <30 mL/min/1.73 m2
Fluoroquinolones
 Reduce dose by 50% when GFR <15 mL/min/1.73 m2
Tetracyclines
 Reduce dose when GFR <45 mL/min/1.73 m2; can exacerbate uremia
Antifungals
 Reduce maintenance dose of ﬂuconazole by 50% when GFR <45 mL/min/1.73 m2
 Reduce dose of ﬂucytosine when GFR <60 mL/min/1.73 m2
Trimethoprim
 Reduce dose by 50% when GFR <30 mL/min/1.73 m2
 Risk factors for hyperkalemia include high doses, elderly, CKD, or with ACE-I and/or NSAIDs
Hypoglycemics
Sulfonylureas  Avoid mainly renally excreted agents (eg, glyburide/glibenclamide)
 Agents mainly metabolized by the liver may need reduced dose when GFR <30 mL/min/1.73
m2 (eg, gliclazide, gliquidone)
Insulin  Partly renally excreted and may need reduced dose when GFR <30 mL/min/1.73 m2
Metformin  Avoid when GFR <30 mL/min/1.73 m2, but consider risk-beneﬁt if GFR is stable
 Review use when GFR <45 mL/min/1.73 m2
 Hold in patients during acute illness or before intravenous radiocontrast
Lipid-lowering
Statins  No increased toxicity for simvastatin 20 mg/d when GFR <30 mL/min/1.73 m2
 Dose reduction/increased toxicity for GFR <30 mL/min/1.73 m2 for lovastatin, pravastatin,
and rosuvastatin
Fenoﬁbrate  Associated with elevations in serum creatinine without a true change in GFR
158 The American Journal of Medicine, Vol 129, No 2, February 2016with an estimated glomerular ﬁltration rate<60mL/min/1.73
m2. Furthermore, they should be used with extreme caution in
patients with chronic kidney disease and concomitant RAAS
blocking agents and/or diuretic therapy.4,9Metformin
Although the US Food and Drug Administration has a black-
box warning for metformin use in patients with serum creat-
inine1.5mg/dL inmen and1.4mg/dL inwomen owing to
an increased risk for lactic acidosis, it is now recognized thatthis risk is extremely low.38,39 Many practice guidelines
recommend discontinuing metformin use only when the
estimated glomerular ﬁltration rate is <30 mL/min/1.73 m2,
and usewith caution for patients with an estimated glomerular
ﬁltration rate of 30-45 mL/min/1.73 m2.4,9,28Iodinated Contrast
The major risk factor for contrast-induced nephropathy is
chronic kidney disease. Use of N-acetylcysteine to prevent
contrast-induced acute kidney injury is not consistently
Table 1 Continued
Agents Cautionary Notes for Common Outpatient Medications
Anticoagulants
Low-molecular-weight heparins  Reduce dose by 50% when GFR <30 mL/min/1.73 m2
 Consider switch to conventional heparin or monitor plasma anti-factor Xa in those at high risk
for bleeding
Warfarin  Increased risk of bleeding when GFR <30 mL/min/1.73 m2
Direct oral anticoagulants  If GFR is <60 mL/min/1.73 m2, conﬁrm correct dosing because recommended dose varies
by indication and level of kidney function. Additionally, assess for potential drug interactions
for inhibitors or inducers of CYP34A and P-gp metabolism. Note that if there are bleeding
complications, the anticoagulant effects of these agents are more difﬁcult to reverse compared
with warfarin.
 Suggested doses for nonvalvular atrial ﬁbrillation follow:
Apixiban 5 mg twice daily:
eGFR 15-60 mL/min/1.73 m2 reduce dose 2.5 mg twice daily
eGFR <15 mL/min/1.73 m2 avoid use, limited data
Dabigatran 150 mg twice daily:
eGFR 30-60 mL/min/1.73 m2 reduce dose 75 mg twice daily
eGFR<30 mL/min/1.73 m2 avoid use
Rivaroxiban 20 mg daily:
eGFR 15-60 mL/min/1.73 m2 reduce dose 15 mg daily
eGFR <15 mL/min/1.73 m2 avoid use
Miscellaneous
Lithium  Nephrotoxic and may cause diabetes insipidus with prolonged use
 Monitor GFR, electrolytes, and lithium levels every 6 mo or more frequently if the dose
increases or the patient is acutely ill
 Avoid using NSAIDs
 Maintain hydration during acute illness
Bisphosphonates  Most are not recommended when GFR <30 mL/min/1.73 m2
 Refer to bone specialist if GFR <30 mL/min/1.73 m2 and no evidence of CKD-MBD
(calcium, phosphate, alkaline phosphatase, and intact PTH normal)
Oral sodium phosphate
containing bowel preparations
 Can cause AKI
 Risk factors are CKD, >60 y of age, female gender, HTN, diabetes, CHF, volume depletion,
active colitis, and medications that may predispose to AKI (RAAS blockers, diuretics, lithium
and NSAIDs)
Gabapentin  Altered mental status, myoclonus, and asterixis with severe CKD
 GFR 30-59 mL/min/1.73 m2: 200-700 mg twice daily
 GFR 15-29 mL/min/1.73 m2: 200-700 mg daily
 GFR <15 mL/min/1.73 m2: 300 mg every 2 days
 Extended release: GFR 30-59 mL/min/1.73m2: 600-1800 mg daily; GFR <30 mL/min/1.73m2:
not recommended
See reference 35 for details on direct oral anticoagulant comments. This is a partial list. Many other medications require dose adjustment for eGFR.
ACE-I ¼ angiotensin-converting enzyme inhibitor; AKI ¼ acute kidney injury; ARB ¼ angiotensin receptor blocker; CHF ¼ congestive heart failure;
CKD ¼ chronic kidney disease; CKD-MBD ¼ CKD mineral and bone disorder; eGFR ¼ estimated glomerular ﬁltration rate; HTN ¼ hypertension;
NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs; PTH ¼ parathyroid hormone; RAAS ¼ renin angiotensin aldosterone system.
Modiﬁed with permission from reference 4
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tion has little risk.40 Other preventive strategies include
minimizing the dose of contrast, volume expansion with
intravenous isotonic saline or bicarbonate, and consideration
of holding medications that increase risk of acute kidney
injury or complications (eg, NSAIDs, diuretics, RAAS bl-
ockers, metformin).4,9,40 Most studies suggest hydration with
isotonic ﬂuids at a rate of 1 mL/kg/h, ideally started at least 1
hour before the procedure and continued for 3-6 hours after-
wards.40 The kidney function should be measured 48-96
hours after exposure during the peak in the incidence of
contrast-induced acute kidney injury.TOPIC 4: CHRONIC KIDNEY DISEASE AND
CARDIOVASCULAR DISEASE
Overview
All people with chronic kidney disease should be considered
at increased risk for cardiovascular disease.1,4,9 In addition to
well-known Framingham risk factors for cardiovascular dis-
ease, low estimated glomerular ﬁltration rate and albuminuria
have been reported to be independently predictive of cardio-
vascular disease and cardiovascular disease mortality in
prospective cohort studies (Figure 1).4 Other chronic kidney
diseaseespeciﬁc risk factors (anemia, mineral and bone
Table 2 Recommendations for Referral to Nephrology Services
 GFR <30 mL/min/1.73 m2 (GFR categories G4-G5)*
 A 25% drop in eGFR
 Progression of CKD with a sustained decline in eGFR of more than
5 per year†
 A consistent ﬁnding of signiﬁcant albuminuria‡
 Persistent unexplained hematuria
 Secondary hyperparathyroidism, persistent anion gap acidosis,
noneiron deﬁciency anemia
 CKD and hypertension refractory to treatment with 4 or more
antihypertensive agents
 Persistent abnormalities of serum potassium
 Recurrent or extensive nephrolithiasis
 Hereditary kidney disease or unknown cause of CKD
CKD¼ chronic kidney disease; eGFR ¼ estimated glomerular ﬁltration
rate.
*If this is a stable isolated ﬁnding, formal referral (ie, formal
consultation and ongoing care management) may not be necessary, and
advice from specialist services may be all that is required to facilitate
best care for the patients. This will be healthcare system dependent.
†Progression of CKD is deﬁned as 1 or more of the following: (1) a
decline in GFR category accompanied by a 25% drop in eGFR from
baseline; and/or (2) rapid progression of CKD, deﬁned as a sustained
decline in eGFR of more than 5 mL/min/1.73 m2/y.
‡Signiﬁcant albuminuria is deﬁned as albumin-to-creatinine ratio
300 mg/g (30 mg/mmol) or albumin excretion rate 300 mg/24 h,
approximately equivalent to protein-to-creatinine ratio 500 mg/g
(50 mg/mmol) or protein excretion rate 500 mg/24 h.
This table is adapted from reference 4.
160 The American Journal of Medicine, Vol 129, No 2, February 2016disease, and vascular calciﬁcation) seem to also play a role in
cardiovascular disease in patients with chronic kidney
disease.Lipid Management: Fire and Forget Strategy in
Chronic Kidney Disease
Guidelines for lipid management in adults no longer mandate
treating to a low-density lipoprotein cholesterol (LDL-C) target
of 70 or 100 mg/dL, because it has not been shown to be
beneﬁcial in clinical trials.41 Randomized controlled trials of
ﬁxed-dose statin-based therapies in chronic kidney disease
have shown a reduced risk of primary and secondary athero-
sclerotic events, but no beneﬁt has been demonstrated for all-
cause mortality or slower progression of chronic kidney dis-
ease.41,42 Lipid-lowering therapy in persons with chronic
kidney disease who are aged 50 years should be based on
assessing cardiovascular disease risk instead of an elevated
LDL-C level.41 Among adults with chronic kidney disease
aged 18-49 years, treatment with lipid-lowering therapy is
indicated for those with known coronary disease (myocardial
infarction or coronary revascularization); diabetes mellitus;
prior ischemic stroke; or an estimated 10-year risk of coronary
death or nonfatal myocardial infarction greater than 10%.41,43
The currently recommended “ﬁre and forget” strategy in-
volves the following steps: (1) exclude remediable causes of
secondary dyslipidemia (eg, nephrotic syndrome, hypothy-
roidism, and certain drugs); (2) assess for risk factors thatwarrant lipid-lowering therapy and initiatewhen indicated; and
(3) do not remeasure LDL-C unless results would alter man-
agement.41 This last step has been particularly controversial.
Measuring a lipid proﬁle 6-12 weeks after initiating statins
might be useful to ensure that an adequate (30%) decline in
LDL-C is observed, and poor adherence or inadequate
response should be considered if this goal is not achieved.41
Many believe that continued periodic monitoring is neces-
sary to assess ongoing adherence and for lipid alterations
associated with chronic kidney disease progression.41Antiplatelet Agents in Chronic Kidney Disease
Adults with chronic kidney disease should be advised to take
low-dose aspirin for secondary prevention of cardiovascular
disease unless the risk of bleeding outweighs the beneﬁts.4,9
Unlike NSAIDs, low-dose aspirin is not associated with acute
kidney injury or rapid chronic kidney disease progression.44TOPIC 5: REFERRAL TO NEPHROLOGISTS
Overview
Primary care clinicians play a central role in referral to
specialists and care coordination for patients with chronic
kidney disease. Timely referral to subspecialty care affords
sufﬁcient time to plan and prepare patients for kidney
replacement therapy, as well as allowing for coordination of
interventions to prevent chronic kidney disease progression
and management of chronic kidney disease complications.
Timely referral has been consistently shown to improve
preparation for kidney replacement therapy, lower use of
hemodialysis catheters and emergent hemodialysis, and in-
crease use of transplantation and self-care dialysis (perito-
neal dialysis and home hemodialysis).45-48 Studies also
suggest that timely referral improves outcomes, including
clinical status at kidney replacement initiation; improved
management of chronic kidney diseaseerelated comorbid-
ities; and improved survival.45 In most cases the primary
care practitioner should continue to share care with the
specialist because they provide complementary services.
Nephrology Referral Recommendations
Indications for nephrology referral are shown in Table 2.4
The primary care clinician may choose not to refer many
patients with severe albuminuria, especially those who have
a clear etiology, such as diabetes. For those categories
marked with an asterisk in Figure 1, clinicians may wish to
review the need to refer with a nephrology consultant on the
basis of availability and the clinical context.
Conservative management without kidney replacement
therapy may be appropriate for patients with stage G4 and
G5 chronic kidney disease and limited life expectancy or
conditions such as advanced dementia, where the burden of
dialysis may outweigh its beneﬁts. Conservative manage-
ment involves medical therapy as well as treating patient
symptoms (eg, pruritis, pain) and psychosocial needs
Vassalotti et al Detection and Management of Chronic Kidney Disease 161including hospice care and other end-of-life concerns. The
nephrologist may be able to assist primary care clinicians to
help the patient and their family make individualized de-
cisions that reﬂect best evidence in addition to their personal
values and preferences.
A common challenge for primary care clinicians is
exempliﬁed by a patient aged 65 years who has an esti-
mated glomerular ﬁltration rate of 45-60 mL/min/1.73 m2
but no albuminuria or urinalysis abnormalities. It is
controversial whether this patient’s kidney function reﬂects
normal aging or chronic kidney disease.49 These patients
should be managed conservatively by avoiding use of
RAAS blockers50 and limiting NSAID and contrast expo-
sures. Last, elderly with laboratory evidence of stage G3a
chronic kidney disease should be monitored closely for
acute kidney injury after major surgical procedures, partic-
ularly cardiac surgery.51
CONCLUSION
Diabetes and hypertension present the dominant risk factors
for chronic kidney disease. Testing, risk stratiﬁcation, and
treatment plans differ according to estimated glomerular ﬁ-
ltration rate and urinary albumin/creatinine ratio. The major
approaches to chronic kidney disease therapy include avoid-
ance of exacerbating drugs, tests and interventions, and
expectant treatment of chronic kidney disease to slow pro-
gression and reduce complications, including cardiovascular
disease. A practical approach to detection andmanagement of
chronic kidney disease is provided in Figure 2.
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Kidney Disease: Improving Global Outcomes
(KDIGO) Chronic Kidney Disease (CKD)
Guideline Statements1
Deﬁnition of CKD.
1.1.1: CKD is deﬁned as abnormalities of kidney struc-
ture or function, present for >3 months, with implication for
health. (Not Graded)
Staging of CKD.
1.2.1: We recommend that CKD is classiﬁed based on
cause, glomerular ﬁltration rate (GFR) category, and albu-
minuria category (CGA). (1B)
1.2.2: Assign cause of CKD based on presence or
absence of systemic disease and the location within the
kidney of observed or presumed pathologiceanatomic
ﬁndings. (Not Graded)
1.2.3: Assign GFR categories (Figure 1). (Not Graded)
1.2.4: Assign albuminuria* categories (Figure 1). (Not
Graded)
Predicting Prognosis of CKD.
1.3.1: In predicting risk for outcome of CKD, identify
the following variables: 1) cause of CKD; 2) GFR category;
3) albuminuria category; 4) other risk factors and comorbid
conditions. (Not Graded)
1.3.2: In people with CKD, use estimated risk of con-
current complications and future outcomes to guide de-
cisions for testing and treatment for CKD complications
(Figure 1). (Not Graded)
1.3.3: In populations with CKD, group GFR and albu-
minuria categories with similar relative risk for CKD out-
comes into risk categories (Figure 1). (Not Graded)
Evaluation of CKD.
1.4.1: Evaluation of chronicity
1.4.1.1: In people with GFR <60 mL/min/1.73 m2 (GFR
categories G3a-G5) or markers of kidney damage, review
past history and previous measurements to determine
duration of kidney disease. (Not Graded)
 If duration is >3 months, CKD is conﬁrmed. Follow
recommendations for CKD.
 If duration is not >3 months or unclear, CKD is not
conﬁrmed. Patients may have CKD or acute kidney dis-
eases (including acute kidney injury [AKI]) or both, and
tests should be repeated accordingly.
1.4.2: Evaluation of cause
1.4.2.1: Evaluate the clinical context, including personal
and family history, social and environmental factors, med-
ications, physical examination, laboratory measures, imag-
ing, and pathologic diagnosis to determine the causes of
kidney disease. (Not Graded)*Note that where albuminuria measurement is not available, urine re-
agent strip results can be substituted.1.4.3: Evaluation of GFR
1.4.3.1: We recommend using serum creatinine and a
GFR estimating equation for initial assessment. (1A)
1.4.3.2: We suggest using additional tests (such as cys-
tatin C or a clearance measurement) for conﬁrmatory testing
in speciﬁc circumstances when eGFR based on serum
creatinine is less accurate. (2B)
1.4.3.3: We recommend that clinicians (1B):
 use a GFR estimating equation to derive GFR from serum
creatinine (eGFRcreat) rather than relying on the serum
creatinine concentration alone.
 understandclinical settings inwhich eGFRcreat is less accurate.
1.4.3.4:We recommend that clinical laboratories should (1B):
 measure serum creatinine using a speciﬁc assay with
calibration traceable to the international standard refer-
ence materials and minimal bias compared with isotope-
dilution mass spectrometry reference methodology.
 report eGFRcreat in addition to the serum creatinine con-
centration in adults and specify the equation used when-
ever reporting eGFRcreat.
 report eGFRcreat in adults using the 2009 Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) creati-
nine equation. An alternative creatinine-based GFR esti-
mating equation is acceptable if it has been shown to
improve accuracy of GFR estimates compared with the
2009 CKD-EPI creatinine equation.
When reporting serum creatinine:
 We recommend that serum creatinine concentration be
reported and rounded to the nearest whole number when
expressed as standard international units (mmol/L) and
rounded to the nearest 100th of a whole number when
expressed as conventional units (mg/dL).
When reporting eGFRcreat:
 We recommend that eGFRcreat should be reported and
rounded to the nearest whole number and relative to a
body surface area of 1.73 m2 in adults using the units mL/
min/1.73 m2.
 We recommend eGFRcreat levels less than 60 mL/min/
1.73 m2 should be reported as “decreased.”
1.4.3.5: We suggest measuring cystatin C in adults with
eGFRcreat 45-59 mL/min/1.73 m
2 who do not have markers
of kidney damage if conﬁrmation of CKD is required. (2C)
 If eGFRcys/eGFRcreat-cys is also <60 mL/min/1.73 m2, the
diagnosis of CKD is conﬁrmed.
 If eGFRcys/eGFRcreat-cys is 60 mL/min/1.73 m2, the
diagnosis of CKD is not conﬁrmed.
1.4.3.6: If cystatin C is measured, we suggest that health
professionals (2C):
 use a GFR estimating equation to derive GFR from serum
cystatin C rather than relying on the serum cystatin C
concentration alone.
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eGFRcreat-cys are less accurate.
1.4.3.7: We recommend that clinical laboratories that
measure cystatin C should (1B):
 measure serum cystatin C using an assay with calibration
traceable to the international standard reference material.
 report eGFR from serum cystatin C in addition to the serum
cystatin C concentration in adults and specify the equation
used whenever reporting eGFRcys and eGFRcreat-cys.
 report eGFRcys and eGFRcreat-cys in adults using the 2012
CKD-EPI cystatin C and 2012 CKD-EPI creatinine-cys-
tatin C equations, respectively, or alternative cystatin C-
based GFR estimating equations if they have been shown
to improve accuracy of GFR estimates compared with the
2012 CKD-EPI cystatin C and 2012 CKD-EPI creatinine-
cystatin C equations.
When reporting serum cystatin C:
 We recommend reporting serum cystatin C concentration
rounded to the nearest 100th of a whole number when
expressed as conventional units (mg/L).
When reporting eGFRcys and eGFRcreat-cys:
 We recommend that eGFRcys and eGFRcreat-cys be re-
ported and rounded to the nearest whole number and
relative to a body surface area of 1.73 m2 in adults using
the units mL/min/1.73 m2.
 We recommend eGFRcys and eGFRcreat-cys levels less than
60 mL/min/1.73 m2 should be reported as “decreased.”
1.4.3.8: We suggest measuring GFR using an exogenous
ﬁltration marker under circumstances where more accurate
ascertainment of GFR will impact on treatment decisions.
(2B)
Evaluation of Albuminuria.
1.4.4.1: We suggest using the following measurements
for initial testing of proteinuria (in descending order of
preference, in all cases an early morning urine sample is
preferred (2B);
1) urine albumin-to-creatinine ratio (ACR);
2) urine protein-to-creatinine ratio (PCR);
3) reagent strip urinalysis for total protein with automated
reading;
4) reagent strip urinalysis for total protein with manual
reading;
1.4.4.2: We recommend that clinical laboratories report
ACR and PCR in untimed urine sample in addition to al-
bumin concentration or proteinuria concentrations rather
than concentrations alone. (1B)
1.4.4.2.1: The term microalbuminuria should no longer
be used by laboratories. (Not Graded)
1.4.4.3: Clinicians need to understand settings that may
affect interpretation of measurements of albuminuria and
order conﬁrmatory tests as indicated (Not Graded): Conﬁrm reagent strip positive albuminuria and proteinuria
by quantitative laboratory measurement and express as a
ratio to creatinine wherever possible.
 Conﬁrm ACR >30 mg/g (>3 mg/mmol) on a random
untimed urine with a subsequent early morning urine
sample.
 If a more accurate estimate of albuminuria or total pro-
teinuria is required, measure albumin excretion rate or
total protein excretion rate in a timed urine sample.
1.4.4.4: If signiﬁcant non-albumin proteinuria is sus-
pected, use assays for speciﬁc urine proteins (e.g.,
a1-microglobulin, monoclonal heavy or light chains [known
in some countries as “Bence Jones” proteins]). (Not Graded)
Deﬁnition and Identiﬁcation of CKD Progression.
2.1.1: Assess GFR and albuminuria at least annually in
people with CKD. Assess GFR and albuminuria more often
for individuals at higher risk of progression, and/or where
measurement will impact therapeutic decisions. (Not Graded)
2.1.2: Recognize that small ﬂuctuations in GFR are
common and are not necessarily indicative of progression.
(Not Graded)
2.1.3: Deﬁne CKD progression on the basis of one of
more of the following (Not Graded):
 Decline in GFR category (90 [G1], 60-89 [G2], 45-59
[G3a], 30-44 [G3b], 15-29 [G4], <15 [G5] mL/min/1.73
m2). A certain drop in eGFR is deﬁned as a drop in GFR
category accompanied by a 25% or greater drop in eGFR
from baseline.
 Rapid progression is deﬁned as a sustained decline in
eGFR of more than 5 mL/min/1.73 m2/y.
 The conﬁdence in assessing progression is increased with
increasing number of serum creatinine measurements and
duration of follow-up.
2.1.4: In people with CKD progression, as Recommen-
dation 2.1.3, review current management, examine for
reversible causes of progression, and consider referral to a
specialist. (Not Graded)
Predictors of Progression.
2.2.1: Identify factors associated with CKD progression
to inform prognosis. These include cause of CKD, level of
GFR, level of albuminuria, age, sex, race/ethnicity, elevated
BP, hyperglycemia, dyslipidemia, smoking, obesity, history
of cardiovascular disease, ongoing exposure to nephrotoxic
agents, and others. (Not Graded)
Prevention of CKD Progression. Blood pressure (BP) and
renin angiotensin aldosterone system (RAAS) interruption
3.1.1: Individualize BP targets and agents according to age,
coexistent cardiovascular disease and other comorbidities,
risk of progression of CKD, presence or absence of reti-
nopathy (in CKD patients with diabetes), and tolerance of
treatment as described in the KDIGO 2012 Blood Pressure
Guideline. (Not Graded)
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postural hypotension regularly when treating CKD patients
with BP-lowering drugs. (Not Graded)
3.1.3: Tailor BP treatment regimens in elderly patients
with CKD by carefully considering age, comorbidities, and
other therapies, with gradual escalation of treatment and close
attention to adverse events related to BP treatment, including
electrolyte disorders, acute deterioration in kidney function,
orthostatic hypotension, and drug side effects. (Not Graded)
3.1.4: We recommend that in both diabetic and nondia-
betic adults with CKD and urine albumin excretion <30 mg/
24 hours (or equivalent) whose ofﬁce BP is consistently
>140 mm Hg systolic or >90 mm Hg diastolic be treated
with BP-lowering drugs to maintain a BP that is consistently
140 mm Hg systolic and 90 mm Hg diastolic. (1B)
3.1.5: We suggest that in both diabetic and nondiabetic
adults with CKD and with urine albumin excretion of 30
mg/24 hours (or equivalent) whose ofﬁce BP is consistently
>130 mm Hg systolic or >80 mm Hg diastolic be treated
with BP-lowering drugs to maintain a BP that is consistently
130 mm Hg systolic and 80 mm Hg diastolic. (2D)
3.1.6: We suggest that an angiotensin receptor blocker
(ARB) or angiotensin-converting enzyme inhibitor (ACE-I)
be used in diabetic adults with CKD and urine albumin
excretion 30-300 mg/24 hours (or equivalent). (2D)
3.1.7: We recommend that an ARB or ACE-I be used in
both diabetic and nondiabetic adults with CKD and urine
albumin excretion >300 mg/24 hours (or equivalent). (1B)
3.1.8: There is insufﬁcient evidence to recommend
combining an ACE-I with ARBs to prevent progression of
CKD. (Not Graded)
3.1.9: We recommend that in children with CKD, BP-
lowering treatment is started when BP is consistently
above the 90th percentile for age, sex, and height. (1C)
3.1.10: We suggest that in children with CKD (particu-
larly those with proteinuria), BP is lowered to consistently
achieve systolic and diastolic readings less than or equal to
the 50th percentile for age, sex, and height, unless achieving
these targets is limited by signs or symptoms of hypoten-
sion. (2D)
3.1.11: We suggest that an ARB or ACE-I be used in
children with CKD in whom treatment with BP-lowering
drugs is indicated, irrespective of the level of proteinuria.
(2D)
CKD and risk of AKI
3.1.12: We recommend that all people with CKD are
considered to be at increased risk of AKI. (1A)
3.1.12.1: In people with CKD, the recommendations
detailed in the KDIGO AKI Guideline should be followed
for management of those at risk of AKI during intercurrent
illness, or when undergoing investigation and procedures
that are likely to increase the risk of AKI. (Not Graded)
Protein intake
3.1.13: We suggest lowering protein intake to 0.8 g/kg/d in
adults with diabetes (2C) or without diabetes (2B) and GFR
<30 mL/min/1.73 m2 (GFR categories G4-G5), with
appropriate education.3.1.14: We suggest avoiding high protein intake (>1.3 g/
kg/d) in adults with CKD at risk of progression. (2C)
Glycemic control
3.1.15: We recommend a target hemoglobin A1c (HbA1c) of
w7.0% (53 mmol/mol) to prevent or delay progression of
the microvascular complications of diabetes, including dia-
betic kidney disease. (1A)
3.1.16: We recommend not treating to an HbA1c target of
<7.0%(<53mmol/mol) inpatients at riskofhypoglycemia. (1B)
3.1.17: We suggest that target HbA1c be extended above
7.0% (53 mmol/mol) in individuals with comorbidities or
limited life expectancy and risk of hypoglycemia. (2C)
3.1.18: In peoplewith CKD and diabetes, glycemic control
should be part of a multifactorial intervention strategy
addressing blood pressure control and cardiovascular risk,
promoting the use of angiotensin-converting enzyme inhibi-
tion or angiotensin receptor blockade, statins, and antiplatelet
therapy where clinically indicated. (Not Graded)
Salt intake
3.1.19: We recommend lowering salt intake to <90 mmol
(<2 g) per day of sodium (corresponding to 5 g of sodium
chloride) in adults, unless contraindicated (see rationale). (1C)
3.1.19.1: We recommend restriction of sodium intake for
children with CKD who have hypertension (systolic and/or
diastolic blood pressure >95th percentile) or pre-
hypertension (systolic and/or diastolic blood pressure >90th
percentile and >95th percentile), following the age-based
Recommended Daily Intake. (1C)
3.1.19.2: We recommend supplemental free water and
sodium supplements for children with CKD and polyuria to
avoid chronic intravascular depletion and to promote
optimal growth. (1C)
Hyperuricemia
3.1.20: There is insufﬁcient evidence to support or refute the
use of agents to lower serum uric acid concentrations in
people with CKD and either symptomatic or asymptomatic
hyperuricemia in order to delay progression of CKD. (Not
Graded)
Lifestyle
3.1.21: We recommend that people with CKD be encour-
aged to undertake physical activity compatible with car-
diovascular health and tolerance (aiming for at least 30
minutes 5 times per week), achieve a healthy weight (body
mass index 20-25 kg/m2, according to country-speciﬁc de-
mographics), and stop smoking. (1D)
Additional dietary advice
3.1.22: We recommend that individuals with CKD receive
expert dietary advice and information in the context of an
education program, tailored to severity of CKD and the need
to intervene on salt, phosphate, potassium, and protein
intake where indicated. (1B)
Complications Associated with Loss of Kidney Func-
tion.
Deﬁnition and identiﬁcation of anemia in CKD
3.2.1: Diagnose anemia in adults and children>15 years with
CKDwhen the Hb concentration is<13.0 g/dL (<130 g/L) in
males and <12.0 g/dL (<120 g/L) in females. (Not Graded)
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concentration is <11.0 g/dL (<110 g/L) in children 0.5-5
years, <11.5 g/dL (115 g/L) in children 5-12 years, and
<12.0 g/dL (120 g/L) in children 12-15 years. (Not Graded)
Evaluation of anemia in people with CKD
3.2.3: To identify anemia in people with CKD measure Hb
concentration (Not Graded):
 when clinically indicated in people with GFR 60 mL/
min/1.73 m2 (GFR categories G1-G2);
 at least annually in people with GFR 30e59 mL/min/1.73
m2 (GFR categories G3a-G3b);
 at least twice per year in people with GFR <30 mL/min/
1.73 m2 (GFR categories G4-G5).
CKD Metabolic Bone Disease Including Laboratory
Abnormalities.
3.3.1: We recommend measuring serum levels of cal-
cium, phosphate, parathyroid hormone (PTH), and alkaline
phosphatase activity at least once in adults with GFR <45
mL/min/1.73 m2 (GFR categories G3b-G5), to determine
baseline values and inform prediction equations if used. (1C)
3.3.2: We suggest not to perform bone mineral density
testing routinely in those with eGFR <45 mL/min/1.73 m2
(GFR categories G3b-G5), because information may be
misleading or unhelpful. (2B)
3.3.3: In people with GFR <45 mL/min/1.73 m2 (GFR
categories G3b-G5), we suggest maintaining serum phos-
phate concentrations in the normal range according to local
laboratory reference values. (2C)
3.3.4: In people with GFR <45 mL/min/1.73 m2 (GFR
categories G3b-G5) the optimal PTH level is not known. We
suggest that people with levels of intact PTH above the upper
normal limit of the assay are ﬁrst evaluated for hyper-
phosphatemia, hypocalcemia, and vitamin D deﬁciency. (2C)
Vitamin D supplementation and bisphosphonates in people with CKD
3.3.5: We suggest not to routinely prescribe vitamin D
supplements or vitamin D analogs, in the absence of sus-
pected or documented deﬁciency, to suppress elevated PTH
concentrations in people with CKD not on dialysis. (2B)
3.3.6: We suggest not to prescribe bisphosphonate
treatment in people with GFR <30 mL/min/1.73 m2 (GFR
categories G4-G5) without a strong clinical rationale. (2B)
Acidosis.
3.4.1: We suggest that in people with CKD and serum
bicarbonate concentrations <22 mmol/L treatment with oral
bicarbonate supplementation be given to maintain serum
bicarbonate within the normal range, unless contraindicated.
(2B)
CKD and Cardiovascular Disease (CVD).
4.1.1: We recommend that all people with CKD be
considered at increased risk for CVD. (1A)
4.1.2: We recommend that the level of care for ischemic
heart disease offered to people with CKD should not be
prejudiced by their CKD. (1A)4.1.3: We suggest that adults with CKD at risk for
atherosclerotic events be offered treatment with antiplatelet
agents unless there is an increased bleeding risk that needs
to be balanced against the possible cardiovascular beneﬁts.
(2B)
4.1.4: We suggest that the level of care for heart failure
offered to people with CKD should be the same as is offered
to those without CKD. (2A)
4.1.5: In people with CKD and heart failure, any esca-
lation in therapy and/or clinical deterioration should prompt
monitoring of eGFR and serum potassium concentration.
(Not Graded)
Caveats When Interpreting Tests for CVD in People
with CKD.
Brain natriuretic peptide (BNP)/N-terminal-proBNP (NT-proBNP)
4.2.1: In people with GFR <60 mL/min/1.73 m2 (GFR
categories G3a-G5), we recommend that serum concentra-
tions of BNP/NT-proBNP be interpreted with caution and in
relation to GFR with respect to diagnosis of heart failure and
assessment of volume status. (1B)
Troponins
4.2.2: In people with GFR <60 mL/min/1.73 m2 (GFR
categories G3a-G5), we recommend that serum concentra-
tions of troponin be interpreted with caution with respect to
diagnosis of acute coronary syndrome. (1B)
Noninvasive testing
4.2.3: We recommend that people with CKD presenting
with chest pain should be investigated for underlying car-
diac disease and other disorders according to the same local
practice for people without CKD (and subsequent treatment
should be initiated similarly). (1B)
4.2.4: We suggest that clinicians are familiar with the
limitations of noninvasive cardiac tests (eg, exercise elec-
trocardiography [ECG], nuclear imaging, echocardiography,
etc) in adults with CKD and interpret the results accord-
ingly. (2B)
CKD and Peripheral Arterial Disease.
4.3.1: We recommend that adults with CKD be regularly
examined for signs of peripheral arterial disease and be
considered for usual approaches to therapy. (1B)
4.3.2: We suggest that adults with CKD and diabetes are
offered regular podiatric assessment. (2A)
Medication Management and Patient Safety in CKD.
4.4.1: We recommend that prescribers should take GFR
into account when drug dosing. (1A)
4.4.2: Where precision is required for dosing (due to
narrow therapeutic or toxic range) and/or estimates may be
unreliable (eg, owing to low muscle mass), we recommend
methods based upon cystatin C or direct measurement of
GFR. (1C)
4.4.3: We recommend temporary discontinuation of
potentially nephrotoxic and renally excreted drugs in people
with a GFR <60 mL/min/1.73 m2 (GFR categories G3a-G5)
who have serious intercurrent illness that increases the risk
*If this is a stable isolated ﬁnding, formal referral (ie, formal consul-
tation and ongoing care management) may not be necessary, and advice
from specialist services may be all that is required to facilitate best care for
the patients. This will be health-care system dependent.
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blockers (including ACE-Is, ARBs, aldosterone inhibi-
tors, direct renin inhibitors), diuretics, nonsteroidal anti-
inﬂammatory drugs, metformin, lithium, and digoxin. (1C)
4.4.4: We recommend that adults with CKD seek medical
or pharmacist advice before using over-the-counter medi-
cines or nutritional protein supplements. (1B)
4.4.5: We recommend not using herbal remedies in
people with CKD. (1B)
4.4.6: We recommend that metformin be continued in
people with GFR 45 mL/min/1.73 m2 (GFR categories
G1-G3a); its use should be reviewed in those with GFR 30-
44 mL/min/1.73 m2 (GFR category G3b); and it should be
discontinued in people with GFR <30 mL/min/1.73 m2
(GFR categories G4-G5). (1C)
4.4.7: We recommend that all people taking potentially
nephrotoxic agents such as lithium and calcineurin in-
hibitors should have their GFR, electrolytes, and drug levels
regularly monitored. (1A)
4.4.8: People with CKD should not be denied therapies
for other conditions such as cancer, but there should be
appropriate dose adjustment of cytotoxic drugs according to
knowledge of GFR. (Not Graded)
Imaging Studies.
4.5.1: Balance the risk of acute impairment in kidney
function due to contrast agent use against the diagnostic
value and therapeutic implications of the investigation. (Not
Graded)
Radiocontrast
4.5.2: We recommend that all people with GFR <60 mL/
min/1.73 m2 (GFR categories G3a-G5) undergoing elective
investigation involving the intravascular administration of
iodinated radio contrast media should be managed according
to the KDIGO Clinical Practice Guideline for AKI,
including:
 avoidance of high osmolar agents (1B);
 use of lowest possible radio contrast dose (Not Graded);
 withdrawal of potentially nephrotoxic agents before and
after the procedure (1C);
 adequate hydration with saline before, during, and after
the procedure (1A);
 measurement of GFR 48-96 hours after the procedure (1C).
Gadolinium-based contrast media
4.5.3: We recommend not using gadolinium-containing
contrast media in people with GFR <15 mL/min/1.73 m2
(GFR category G5) unless there is no alternative appropriate
test. (1B)
4.5.4: We suggest that people with a GFR <30 mL/min/
1.73 m2 (GFR categories G4-G5) who require gadolinium
containing contrast media are preferentially offered a
macrocyclic chelate preparation. (2B)
Bowel preparation
4.5.5: We recommend not to use oral phosphate-containing
bowel preparations in people with a GFR <60 mL/min/1.73
m2 (GFR categories G3a-G5) or in those known to be at risk
of phosphate nephropathy. (1A)CKD and Risks for Infections, AKI, Hospitalizations,
and Mortality.
CKD and risk of infections
4.6.1: We recommend that all adults with CKD are offered
annual vaccination with inﬂuenza vaccine, unless contra-
indicated. (1B)
4.6.2: We recommend that all adults with eGFR <30
mL/min/1.73 m2 (GFR categories G4-G5) and those at high
risk of pneumococcal infection (eg, nephrotic syndrome,
diabetes, or those receiving immunosuppression) receive
vaccination with polyvalent pneumococcal vaccine unless
contraindicated. (1B)
4.6.3: We recommend that all adults with CKD who have
received pneumococcal vaccination are offered revaccina-
tion within 5 years. (1B)
4.6.4: We recommend that all adults who are at high risk
of progression of CKD and have GFR <30 mL/min/1.73 m2
(GFR categories G4-G5) be immunized against hepatitis B
and the response conﬁrmed by appropriate serological
testing. (1B)
4.6.5: Consideration of live vaccine should include an
appreciation of the patient’s immune status and should be in
line with recommendations from ofﬁcial or governmental
bodies. (Not Graded)
4.6.6: Pediatric immunization schedules should be fol-
lowed according to ofﬁcial international and regional rec-
ommendations for children with CKD. (Not Graded)
CKD and risk of AKI
4.6.7: We recommend that all people with CKD are
considered to be at increased risk of AKI. (1A)
4.6.7.1: In people with CKD, the recommendations
detailed in the KDIGO AKI Guideline should be followed
for management of those at risk of AKI during intercurrent
illness, or when undergoing investigation and procedures
that are likely to increase the risk of AKI. (Not Graded)
CKD and risk of hospitalization and mortality
4.6.8: CKD disease management programs should be
developed to optimize the community management of
people with CKD and reduce the risk of hospital admission.
(Not Graded)
4.6.9: Interventions to reduce hospitalization and mor-
tality for people with CKD should pay close attention to the
management of associated comorbid conditions and car-
diovascular disease in particular. (Not Graded)
Referral to Specialist Services.
5.1.1: We recommend referral to specialist kidney care
services for people with CKD in the following circum-
stances (1B):
 AKI or abrupt sustained fall in GFR;
 GFR <30 mL/min/1.73 m2 (GFR categories G4-G5)*;
Reference
1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work
Group. KDIGO 2012 clinical practice guideline for the evaluation
and management of chronic kidney disease. Kidney Int Suppl. 2013;3:
1-150.
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300 mg/g [30 mg/mmol] or albumin excretion rate
300 mg/24 hours, approximately equivalent to protein/
creatinine ratio 500 mg/g [50 mg/mmol] or protein
excretion rate 500 mg/24 hours);
 progression of CKD (see Recommendation 2.1.3 for
deﬁnition);
 urinary red cell casts, red blood cells >20 per high-power
ﬁeld sustained and not readily explained;
 CKD and hypertension refractory to treatment with 4 or
more antihypertensive agents;
 persistent abnormalities of serum potassium;
 recurrent or extensive nephrolithiasis;
 hereditary kidney disease.
5.1.2: We recommend timely referral for planning renal
replacement therapy (RRT) in people with progressive CKD
in whom the risk of kidney failure within 1 year is 10-20% or
higher,† as determined by validated risk prediction tools. (1B)
Care of the Patient with Progressive CKD.
5.2.1: We suggest that people with progressive CKD
should be managed in a multidisciplinary care setting. (2B)
5.2.2: The multidisciplinary team should include or have
access to dietary counseling, education and counseling about
different RRT modalities, transplant options, vascular access
surgery, and ethical, psychological, and social care. (Not
Graded)
Timing the Initiation of RRT.
5.3.1: We suggest that dialysis be initiated when 1 or more
of the following are present: symptoms or signs attributable to
kidney failure (serositis, acid base or electrolyte abnormalities,
pruritus); inability to control volume status or blood pressure; a
progressive deterioration in nutritional status refractory to†The aim is to avoid late referral, deﬁned here as referral to specialist
services less than 1 year before start of RRT.dietary intervention; or cognitive impairment. This often but
not invariably occurs in the GFR range between 5 and 10 mL/
min/1.73 m2. (2B)
5.3.2: Living donor pre-emptive renal transplantation in
adults should be considered when the GFR is <20 mL/min/
1.73 m2 and there is evidence of progressive and irreversible
CKD over the preceding 6-12 months. (Not Graded)
Structure and Process of Comprehensive Conservative
Management.
5.4.1: Conservative management should be an option in
people who choose not to pursue RRT and this should be
supported by a comprehensive management program. (Not
Graded)
5.4.2: All CKD programs and care providers should be
able to deliver advance care planning for people with a
recognized need for end-of-life care, including those
people undergoing conservative kidney care. (Not
Graded)
5.4.3: Coordinated end-of-life care should be available to
people and families through either primary care or specialist
care as local circumstances dictate. (Not Graded)
5.4.4: The comprehensive conservative management
program should include protocols for symptom and pain
management, psychological care, spiritual care, and cultur-
ally sensitive care for the dying patient and their family
(whether at home, in a hospice or a hospital setting), fol-
lowed by the provision of culturally appropriate bereave-
ment support. (Not Graded)
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